Smoking status and the effects of antiplatelet drugs.
Department of Internal Medicine, Landesklinikum Waldviertel Zwettl, A-3910 Zwettl, Austria.
Michael M
MM
Hirschl
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology; D012907:Smoking / Q000453:epidemiology; D013876:Thiophenes / Q000494:pharmacology; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000494:pharmacology; D016896:Treatment Outcome
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine; D001241:Aspirin